Molecular drivers in CNS metastatic disease

Area of Science:

• Neuro-oncology
• Medical oncology
• Pharmacology

Background:

• Increasing incidence and prevalence of CNS metastases globally.
• Improved systemic therapies lead to longer survival and increased risk of CNS progression.
• Advances in drug development offer new hope for managing brain metastases.

Purpose of the Study:

• To review and update on drugs demonstrating efficacy in achieving intracranial control of CNS metastases.
• To highlight newer agents with significant nervous system penetration and therapeutic benefits.
• To discuss targeted therapies for specific cancer mutations impacting the CNS.

Main Methods:

• Literature review of recent therapeutic advances in CNS metastases.
• Analysis of drugs with demonstrated efficacy in intracranial and leptomeningeal disease control.
• Overview of ongoing clinical research and challenges in the field.

Main Results:

• Several newer systemic agents show significant CNS penetration and efficacy.
• Targeted therapies are particularly successful in halting CNS cancer cell growth.
• Many reviewed drugs are approved or pending regulatory approval for CNS metastases.

Conclusions:

• Substantial therapeutic progress has been made in managing CNS metastases.
• Emerging drugs and targeted therapies offer improved intracranial control.
• Ongoing research addresses challenges in treating brain metastases and leptomeningeal disease.